Business Wire

Publicis.Sapient and European DataWarehouse to Build Securitisation Repository for New Simple, Transparent and Standardized (STS) Regulation

Jaa

Publicis.Sapient the world’s most advanced digital transformation company, today announced it has been selected by the European DataWarehouse (ED) as its transformation partner to become the first securitisation repository under the new EU regulation for Simple, Transparent and Standardized (STS) securitisations, expected to take effect in 2019.

ED is the designated European repository for loan-level data stemming from Asset Backed Securities (ABS). It was established under European Central Bank's loan-level initiative in 2012. Publicis.Sapient has been the implementation partner of ED since the very beginning. Today more than 500 issuers, investors, central banks and other data users utilise ED’s data infrastructure.

The European Securities and Markets Authority (ESMA) is changing the regulatory framework for the securitisation market in the EU with the introduction of the STS regulation. Under STS, securitisations will be stimulated and mandatory transparency requirements introduced. Loan-level data, investor reports and other related documents must be submitted on a regular basis to an authorised repository. The repositories will then process, validate and store the securitisation related data and assess the data quality of submissions. Issuers, investors and regulators will be enabled to fulfil the STS due diligence requirements and supervise the EU securitisation market.

ED aims to become the first such securitisation repository that will serve regulators, originators, sponsors, investors and rating agencies under the new securitisation regulation. Publicis.Sapient will act as the transformation partner to build out the cloud-hosted platform that will act as a central data repository, providing a seamless experience to ED clients reporting under the European Central Bank requirements and the STS regulatory framework.

“We’re delighted that ED has selected Publicis.Sapient as its strategic transformation partner and that we can continue to help further its mission of delivering transparency in financial markets. By providing a unique, cloud-based platform, ED is creating a modern repository for banks, servicers and other market participants to support compliance with the new securitisation regulation,” said Bernd Harnisch, Vice President of Consulting at Publicis.Sapient.

“The usage of advanced front-end technologies to provide outstanding user experience for the clients of European DataWarehouse and a thorough understanding of the STS regulation are the foundation for designing this data repository. With agile project methodologies, we can rapidly react to regulatory changes and deliver tangible results on a continuous basis,” added Jens Schuback, Senior Manager and Project Lead at Publicis.Sapient.

“At the European DataWarehouse, we have been serving issuers and investors of Asset Backed Securities in the European Union for more than five years,” added Christian Thun, CEO, European DataWarehouse. “The transparency requirements under the new STS regulation will be a challenge for our clients as well as for us. Nonetheless, the European DataWarehouse is determined to become the first securitisation repository under the new STS framework in order to cater for the needs of the market.”

About Publicis.Sapient

Publicis.Sapient, the Digital Business Transformation hub of Publicis Groupe, is purpose-built to help businesses transform for the digital age, enabling seamless adaptation to a world where consumer behavior and technology disruption are catalyzing social and commercial change. With 19,000 people and 100 offices around the globe, our expertise spanning technology, data sciences, consulting and creative enables us to deliver on complex transformation initiatives that accelerate the evolution, growth and value for our clients’ businesses. For more information, visit www.publicis.sapient.com.

About European DataWarehouse (ED)

European DataWarehouse (ED) is the first and the only centralised data repository in Europe for collecting, validating and distributing detailed, standardised and asset class specific loan level data for Asset-Backed Securities (ABS) and private whole loan portfolios. ED stores loan-level data and corresponding documentation for investors and other market participants. Operating as a market infrastructure and designated by the Eurosystem, ED aims to increase transparency and restore confidence in the ABS market. Through ED’s data, users are able to analyse underlying portfolios in a more efficient way and compare portfolios on a systematic basis.

ED currently hosts data for more than 1250 public ABS transactions across Europe.

Contact information

Publicis.Sapient
Geoff Whitehouse, 44 (0) 207 456 6550
Head of PR
gwhitehouse@sapient.com
or
European DataWarehouse GmbH
Diane Wathen, 49 (0) 69 50986 9326
Marketing & Communications Manager
diane.wathen@eurodw.eu

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 10:06Tiedote

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 10:00Tiedote

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 05:53Tiedote

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 17:59Tiedote

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme